• Unique Validation and Training facility supports Biopharmaceutical customers in China
• USD 2 million investment supports Chinese regulatory efforts to improve drug safety
May 11, 2011, Shanghai, China: Merck Millipore, the Life Science division of Merck, today opened its state-of-the-art Biopharmaceutical Technical and Training Center in Shanghai, China. The 2,500 square meter facility will provide support, training and validation services to Merck Millipore’s biopharmaceutical customers with operations in China.
“We are responding to China’s commitment to strengthen regulatory requirements designed to ensure drug safety,” said Jean-Paul Mangeolle, Head of Merck Millipore’s Process Solutions business. “Our new Biopharmaceutical Technical Center is unique in that we can support and even train our pharmaceutical customers to meet the new Chinese and global regulations. Today we have taken a significant step not only expanding our 30 years of local offerings in China, but also to support the effort to produce safe, quality drugs in this important and fast growing region.”
Mangeolle was joined by a number of officials from the Chinese SFDA at today’s opening ceremonies as well as representatives of Peking University. Both institutions will utilize Merck Millipore’s new Technical Center for training courses specifically created for GMP training and Aseptic process manufacturing.
Merck Millipore’s Shanghai Biopharmaceutical Technical Center is located in Zhangjiang Hi-Tech Park and will support area biopharmaceutical manufacturers. The facility will allow local and regional customers to investigate, explore and optimize their upstream and downstream processes as well as environmental monitoring processes with the support of Merck Millipore’s local, regional and international experts. Merck Millipore operates similar facilities in Singapore, Japan, India, France, North America and Brazil.
About Merck Millipore
Merck Millipore is the Life Science division of Merck KGaA of Germany and offers a broad range of innovative, performance products, services and business relationships that enable our customers’ success in research, development and production of biotech and pharmaceutical drug therapies. Through dedicated collaboration on new scientific and engineering insights, and as one of the top three R&D investors in the Life Science Tools industry, Merck Millipore serves as a strategic partner to customers and helps advance the promise of life science.
Headquartered in Billerica, Massachusetts, the division has around 10,000 employees, operations in 68 countries and 2010 revenues of EUR 1.7 billion. Merck Millipore operates as EMD Millipore in the U.S. and Canada.
Note: Merck KGaA or Merck shall mean Merck KGaA, Darmstadt, Germany
All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merck.de/subscribe to register online, change your selection or discontinue this service.
Merck is a global pharmaceutical and chemical company with total revenues of EUR 9.3 billion in 2010, a history that began in 1668, and a future shaped by more than 40,000 employees in 68 countries. Its success is characterized by innovations from entrepreneurial employees. Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S. subsidiary Merck & Co. was expropriated and has been an independent company ever since.
China Association For Pharmaceutical Equipment (CAPE in short) was founded in 1991， who represents the benefits of all its members and maintain their legal rights and interest. Its aim is to serve both the China government and pharmaceutical equipment manufacturing enterprises. CAPE currently has about 255 members, 47 commissioners, 8 deputy head and 11 executive commissioners. It is structured by a secretariat office, a member management department, a technical and economic department, a international department, a web section and an exhibition management department. The main activities of CAPE are as the flowing:
1 Organize and draft Five-Year Plan for pharmaceutical machinery industry; 2．Organize to formulate and revise the state -level and industry-level standards for pharmaceutical equipment manufacturers; 3 Compose books and materials to instruct and guide the development and advancement for pharmaceutical machinery industry; 4 Conduct the Statistics work for pharmaceutical machinery industry; 5 Preside over the self-discipline issues; 6 Evaluate, in early days, the major fundamental constructions, technology reconstructions and new product development in pharmaceutical machinery industry; 7 Appraise and promote scientific and technological achievements for pharmaceutical machinery, organize technological cooperation and exchanges between domestic and international pharmaceutical machinery companies; 8 Participate in the quality examination and certification issuing works for pharmaceutical products; 9 Host China National Pharmaceutical machinery Exhibition; 10 Render the desires and requirements of pharmaceutical machinery enterprises to relevant China government authorities; China pharmaceutical industry manufacturer 8 categories of products, such as
Machines and equipment for medicine materials, preparation machines, pharmaceutical packaging machines, water treating machines for pharmaceutical use, pharmaceutical milling machines, pharmaceutical pulverizing machines, medicine detecting instruments as well as other pharmaceutical machineries. These products meet and satisfy the needs and demands from medicine producers, animal medicine producers, health-care product producers as well as food and cosmetics producers in China. In addition, these products have been also exported to more than eighty countries and areas like United States of America, Canada, Mexico, Argentina, Brazil, Germany, France, England, Italy, Russia, Japan, Korea, Viet Nam, Thailand, Indonesia, Malaysia, the Philippines, Pakistan, Australia, New Zealand, Iran, Iraq, Egypt, Hang Kong and Marco. Our target in "The Eleventh-five Year" is to drive industry innovation through technical innovation; to bring along the industry updating through self-innovation. Attach more importance to people; coordinate from all aspects to keep continual development of pharmaceutical industry as well as to contribute more to the medicine industry home and abroad.